Stem Cell Innovations, Inc. (OTCBB: SCLL) announced yesterday that the Company has opened a new R&D facility to commercialise their proprietary platform of human pluripotent stem cells (PCs™) in Europe. The facility is based in Leiden, the Netherlands and encompasses 1,000 square meters of state-of-the-art research laboratories.
